Answers are grounded in this paper and cite their sources.
The optimization of a potent, class I selective ketone HDAC inhibitor is shown. It possesses optimized pharmacokinetic properties in preclinical species, has a clean off-target profile, and is negative in a microbial mutagenicity (Ames) test. In a mouse xenograft model it shows efficacy comparable to that of vorinostat at a 10-fold reduced dose.
No takes yet. Share an insight, caveat, or question.
Kinzel et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: